Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 2,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 2,000 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $52.88, for a total value of $105,760.00. Following the completion of the sale, the vice president owned 29,891 shares in the company, valued at $1,580,636.08. This trade represents a 6.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Patrick Lamy also recently made the following trade(s):

• On Friday, June 20th, Patrick Lamy sold 875 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.59, for a total value of $47,766.25.
• On Monday, June 16th, Patrick Lamy sold 2,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.14, for a total value of $108,280.00.
• On Tuesday, June 10th, Patrick Lamy sold 919 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total value of $49,626.00.
• On Monday, June 2nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.31, for a total value of $201,240.00.
• On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.00, for a total value of $200,000.00.
• On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $42.49, for a total value of $339,920.00.

Akero Therapeutics Trading Up 0.3%

Akero Therapeutics stock traded up $0.13 during mid-day trading on Friday, hitting $52.01. The stock had a trading volume of 404,821 shares, compared to its average volume of 1,050,314. The stock has a 50-day simple moving average of $48.88 and a two-hundred day simple moving average of $42.92. The stock has a market capitalization of $4.15 billion, a PE ratio of -26.67 and a beta of -0.15. Akero Therapeutics, Inc. has a 12 month low of $21.34 and a 12 month high of $58.40. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. As a group, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on AKRO. Bank of America increased their target price on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Citigroup decreased their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics has an average rating of "Buy" and a consensus target price of $82.50.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AKRO. RTW Investments LP raised its position in Akero Therapeutics by 15.9% in the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after buying an additional 940,388 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Akero Therapeutics by 11.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company's stock worth $194,997,000 after acquiring an additional 495,119 shares during the period. Vanguard Group Inc. boosted its stake in shares of Akero Therapeutics by 14.2% during the 1st quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company's stock worth $171,256,000 after acquiring an additional 526,233 shares during the period. Deep Track Capital LP boosted its stake in Akero Therapeutics by 116.0% in the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock valued at $41,452,000 after purchasing an additional 800,216 shares during the period. Finally, SG Americas Securities LLC boosted its stake in Akero Therapeutics by 93.3% in the 1st quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock valued at $46,786,000 after purchasing an additional 557,794 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.